Recent Finacing
Recent Raise
Teclison is a clinical-stage biotech developing TEC-001, a Trans‑Arterial Embolization (TATE) therapy that induces tumor necrosis and boosts checkpoint inhibitors in liver, colorectal, and lung cancers; in Phase 2.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Teclison.
